股市必读：众生药业10月31日涨停收盘，收盘价19.32元

Core Viewpoint - On October 31, 2025, Zhongsheng Pharmaceutical (002317) closed at 19.32 yuan, reaching the daily limit with a 10.02% increase, indicating strong market interest and trading activity [1][2]. Trading Information Summary - Zhongsheng Pharmaceutical's stock hit the daily limit at 13:32 and remained closed at the limit price, with a closing order amount of 1.26 billion yuan, accounting for 0.86% of its market capitalization [2][9]. - The net inflow of main funds was 318 million yuan, while retail funds experienced a net outflow of 161 million yuan [3]. Shareholder Changes - As of September 30, 2025, the number of shareholders decreased to 72,900, a reduction of 17,000 (18.9%) since June 30, 2025, with the average shareholding increasing from 9,471 shares to 11,700 shares [5][9]. Financial Performance Highlights - For the first three quarters of 2025, Zhongsheng Pharmaceutical reported a main revenue of 1.889 billion yuan, a year-on-year decrease of 1.01%, while the net profit attributable to shareholders increased by 68.4% to 251 million yuan [6]. - In Q3 2025, the single-quarter main revenue was 589 million yuan, up 8.35% year-on-year, with a net profit of 62.68 million yuan, reflecting a 2.1% increase [6]. - The company's non-recurring net profit for Q3 2025 surged by 301.03% year-on-year to 59.03 million yuan [6][9]. Company Debt and Profitability - Zhongsheng Pharmaceutical's debt ratio stands at 20.16%, with investment income reported at 12.82 million yuan and financial expenses at -4.81 million yuan, indicating a strong financial position [7]. Recent Developments in Product Promotion - The company is actively promoting its antiviral drug, Angdilave, through marketing innovations and is focusing on market share expansion despite limited media coverage compared to competitors [8]. - Angdilave has passed preliminary review for inclusion in the medical insurance directory and is progressing through the necessary procedures for potential inclusion [8].